대한의생명과학회지 (Biomedical Science Letters)

  • 제22권2호
  • /
  • Pages.37-45
  • /
  • 2016
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

Distribution of Oncogenic Human Papillomavirus Genotypes at High Grade Cervical Lesions above CIN 2 Grade with Histological Diagnosis

  • Kim, Geehyuk (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Park, Sungyoung (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Wang, Hye-young (M&D, Inc., Wonju Eco Environmental Technology Center) ;
  • Kim, Sunghyun (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan) ;
  • Park, Sangjung (Department of Biomedical Science, College of Life and Health Sciences, Hoseo University) ;
  • Yu, Kwangmin (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Lee, Boohyung (Department of Clinical Laboratory Science, Hyejeon College) ;
  • Ahn, Seung-Ju (Department of Clinical Laboratory Science, Daegu Health & Science College) ;
  • Kim, Eun-Joong (Department of Clinical Laboratory Science, Chungbuk Health & Science University) ;
  • Lee, Dongsup (Department of Clinical Laboratory Science, Hyejeon College)
  • 투고 : 2016.05.18
  • 심사 : 2016.06.28
  • 발행 : 2016.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

High risk human papillomavirus (HR-HPV) is major risk factor for uterine cervical cancer. There are approximately 15 types of HR-HPV. Liquid based cytology samples (116 samples) with high grade cervical lesions belonging to cervical intraepithelial neoplasia (CIN) 2, CIN 3, carcinoma in situ (CIS) and squamous cell carcinoma (SCC) were used after histologic confirmation. HR-HPV genotype assay was conducted using DNA chips. The HR-HPV infection rate was 81.9% with SCC samples showing the highest HR-HPV infection rate of 31%. CIN 3, CIS and CIN 2 showed infection rates of 25%, 16.4% and 9.5%, respectively. According to age with HR HPV infection rate, the 30~39 years-old group showed the highest infection rate by 92.3%. According to distribution with HR HPV genotyping, HPV 16 showed the highest infection rate by 42.3% whereas HPV 33 and HPV 58 showed infection rates of 11.7% and 10.8%, respectively. HPV 18 which is the second most common infected HPV genotype in the world showed 3.6%. Of the three most common oncogenic HR-HPV genotypes in CIN 2, we detected HPV 16, 35, 58; CIN 3 was HPV 16, 33, 58; CIS was HPV 16, 58, 33 (35/52); and SCC was HPV 16, 33, and 18 (31/52/58). Among the HPV 18, CIN 2, CIN 3, CIS and SCC showed 0.9%, 0.9%, 0% and 1.8%, respectively. The most often used preventive vaccines for cervical cancers use HPV 16 and HPV 18 as targets. However, results derived from this study suggest that a preventive vaccine against HPV 16 and HPV 18 would not be optimal for populations in this study.

키워드

참고문헌

  1. Andersson E, Karrberg C, Radberg T, Blomqvist L, Zetterqvist BM, Ryd W, Lindh M, Horal P. Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia. J Clin Microbiol. 2011. 49: 3794-3799. https://doi.org/10.1128/JCM.00549-11
  2. Bao YP, Li N, Smith JS, Qiao YL. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer. 2008. 18: 71-79.
  3. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst. 1995. 87: 796-802. https://doi.org/10.1093/jnci/87.11.796
  4. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. A review of human carcinogens-part B: biological agents. Lancet Oncol. 2009.10: 321-322. https://doi.org/10.1016/S1470-2045(09)70096-8
  5. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010. 202: 1789-1799. https://doi.org/10.1086/657321
  6. Cattani P, Siddu A, D'Onghia S, Marchetti S, Santangelo R, Vellone VG, Zannoni GF, Fadda G. RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus. J Clin Microbiol. 2009. 47: 2136-2141. https://doi.org/10.1128/JCM.01733-08
  7. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005. 366: 991-998. https://doi.org/10.1016/S0140-6736(05)67069-9
  8. Dyson N, Howley PM, Munger K, Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989. 243: 934-940. https://doi.org/10.1126/science.2537532
  9. Ergunay K, Misirlioglu M, Pinar F, Tuncer ZS, Tuncer S, Ustacelebi S. Human papilloma virus DNA in cervical samples with cytological abnormalities and typing of the virus. Mikrobiyol Bul. 2007. 41: 219-226.
  10. Gaarenstroom KN, Melkert P, Walboomers JM, Van Den Brule AJ, Van Bommel PF, Meyer CJ, Voorhorst FJ, Kenemans P, Helmerhorst TJ. Human papillomavirus DNA and genotypes: prognostic factors for progression of cervical intraepithelial neoplasia. Int J Gynecol Cancer. 1994. 4: 73-78. https://doi.org/10.1046/j.1525-1438.1994.04020073.x
  11. Hong SR, Kim IS, Kim DW, Kim MJ, Kim AR, Kim YO, Kim HS, Rha SH, Park GS, Park YK, Park YS, Park HS, Suh KS, Sohn JH, Shin MK, Oh HK, Yun KJ, Yoon HK, Lee SN, Lee AW, Lee HJ, Cho HY, Choi C, Jung WW. Prevalence and genotype distribution of cervical human papillomavirus DNA in Korean women: a multicenter study. Korean J Pathol. 2009. 43: 434-342. https://doi.org/10.4132/KoreanJPathol.2009.43.4.342
  12. Im JE, Shim MJ, Ryang YS, Lee DC. Human papillomavirus testing with hybrid capture II and DNA chip. J Exp Biomed Sci. 2005. 11: 51-56.
  13. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011. 61: 69-90. https://doi.org/10.3322/caac.20107
  14. Laudadio J. Human papillomavirus detection: testing methodologies and their clinical utility in cervical cancer screening. Adv Anat Pathol. 2013. 20: 158-167. https://doi.org/10.1097/PAP.0b013e31828d1893
  15. Levin AJ, Momandd J, Finlay CA. The p53 tumor supressor gene. Nature. 1991. 351: 453-456. https://doi.org/10.1038/351453a0
  16. Kim YK, Park YP. Analysis of telomerase activity by HPV E6/E7 expression in SW13. J Exp Biomed Sci. 2006. 12: 399-403.
  17. Kim SH, Lee DS, Kim Y, Kim GH, Park SJ, Choi YI, Kim TU, Park KH, Lee HY. Clinical evaluation of human papillomavirus DNA genotyping assay to diagnose women cervical cancer. J Exp Biomed Sci. 2012. 18: 123-130.
  18. Kim SH, Lee DS, Park SJ, Kim TU, Jeon BY, Park KH, Lee HY. REBA $HPV-ID^{(R)}$ for efficient genotyping of human papillomavirus in clinical samples from Korean patients. J Med Virol. 2012. 84: 1248-1253. https://doi.org/10.1002/jmv.23334
  19. Lee DS, Kim SH, Park SJ, Jin HW, Kim TU, Park KH, Lee HY. Human papillomavirus prevalence in Gangwon province using reverse blot hybridization assay. Korean J Pathol. 2011. 45: 348-353. https://doi.org/10.4132/KoreanJPathol.2011.45.4.348
  20. Im JA, Shim MJ, Ryang YS, Lee DC. Human papillomavirus testing with Hybrid Capture II and DNA chip. J Exp Biomed Sci. 2005. 11: 51-56.
  21. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and years of publication. Int J Cancer. 2011. 128: 927-935. https://doi.org/10.1002/ijc.25396
  22. Lee DS, Kim GH, Kim SH, Park SY, Wang HY, Park SJ, Han Lin, Yubo Ren, Li Yingxue, Park KH, Lee HY. Human papillomavirus distribution among women in western Shandong province, East China using reverse blot hybridization assay. Biomed Sci Lett. 2015. 21: 69-76. https://doi.org/10.15616/BSL.2015.21.2.69
  23. Okadome M, Saito T, Tanaka H, Nogawa T, Furuta R, Watanabe K, Kita T, Yamamoto K, Mikami M, Takizawa K. Potential impact of combined high- and low-risk human papillomavirus infection on the progression of cervical intraepithelial neoplasia 2. J Obstet Gynaecol Res. 2014. 40: 561-569. https://doi.org/10.1111/jog.12202
  24. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999. 49: 33-64. https://doi.org/10.3322/canjclin.49.1.33
  25. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990. 63: 1129-1136. https://doi.org/10.1016/0092-8674(90)90409-8
  26. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer. 1998. 75: 536-545. https://doi.org/10.1002/(SICI)1097-0215(19980209)75:4<536::AID-IJC8>3.0.CO;2-U
  27. Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol. 2009. 19: 97-113. https://doi.org/10.1002/rmv.605
  28. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009. 384: 260-265. https://doi.org/10.1016/j.virol.2008.11.046